Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
22.40
+2.68 (+13.59%)
Streaming Delayed Price
Updated: 1:10 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Ultragenyx Stock Eyes Best Day In 17 Months As Wall Street Shifts Focus To 2026 Pipeline After Bone Disease Trial Miss
↗
Today 13:00 EST
The rally reflects renewed investor attention on longer-term pipeline catalysts and regulatory milestones rather than the recent late-stage trial setback.
Via
Stocktwits
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
↗
December 29, 2025
A pharmaceutical company's success with a Phase 2 study doesn't guarantee positive results in Phase 3.
Via
The Motley Fool
Which stocks are experiencing notable movement on Monday?
↗
December 29, 2025
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
December 29, 2025
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...
Via
MarketMinute
Topics
ETFs
Intellectual Property
Keep an eye on the top gainers and losers in Monday's session.
↗
December 29, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
Why Did RARE Stock Plunge Over 41% Today?
↗
December 29, 2025
Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program.
Via
Stocktwits
Traders are paying attention to the gapping stocks in Monday's session.
↗
December 29, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via
Chartmill
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate in Investor Conferences in December
November 24, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
November 05, 2025
Via
Benzinga
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
November 04, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
November 04, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
October 30, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
October 28, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 24, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
September 30, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
↗
September 09, 2025
FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.
Via
Benzinga
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
September 08, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts
↗
September 05, 2025
Via
Benzinga
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
↗
September 04, 2025
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
September 02, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx to Participate at Investor Conferences in September
August 29, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
